Adverse effects of SGLT2 inhibitors on bone health
Adverse effects of SGLT2 inhibitors on bone healthAdverse effects of SGLT2 inhibitors on bone health, Published online: 06 June 2018; doi:10.1038/s41581-018-0028-0Sodium–glucose cotransporter 2 (SGLT2) inhibitors provide metabolic and cardiorenal benefits for patients with type 2 diabetes but are associated with a number of safety issues. Here, we discuss evidence suggesting that indirect activation of the FGF23–1,25-dihydroxyvitamin D–parathyroid hormone axis by SGLT2 inhibition might contribute to adverse effects on bone health.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Jenny E. Blau Simeon I. Taylor Source Type: research
More News: Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Hormones | SGLT2 Inhibitors | Urology & Nephrology